Thursday Jun 19
Chairman & CEO Kurt Graves Presents First 'Key Disruptor Award' to...
Intarcia Therapeutics, Inc. Chairman, President and CEO Kurt Graves late yesterday presented the very first "Chairman's Key Disruptor Award" to Thomas Alessi, Ph.D., VP of Early Development and Manufacturing.
Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A...
Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74 Scientific Sessions of the American Diabetes Association held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial with ITCA 650 in type 2 diabetes.
Biotech Veteran-Led Reloads $300 Million To Bankroll Late-Stage Companies
Foresite Capital Closes $300 Million Fund II to Finance Late-stage Healthcare Companies San Francisco, CA, and New York, NY, April 1, 2014: Foresite Capital, a growth equity firm focused on late-stage healthcare investing, today announced the closing of Foresite Capital Fund II, which was oversubscribed and closed with $300 million in capital ... (more)
Intarcia Secures Second Landmark Private Financing of $200 Million -...
Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million.